AstraZeneca receives CDSCO approval of additional indication for trastuzumab deruxtecan
AstraZeneca Pharma India Ltd. said India’s CDSCO approved an additional indication for trastuzumab deruxtecan (100 mg/5 mL vial) for adjuvant treatment of adults with HER2-positive early breast cancer (IHC 3+ or ISH+) who have residual invasive disease after neoadjuvant trastuzumab (with or without pertuzumab) and taxane therapy. The decision cites DESTINY-Breast05 trial results.
How this was made
The 30-second read
Why it matters
This is a new regulatory indication supported by DESTINY-Breast05 trial results, expanding use beyond existing adjuvant options such as T-DM1 for certain high-risk residual disease patients.
Market read
A fresh India regulatory approval for trastuzumab deruxtecan in a high-risk early-stage HER2-positive residual disease segment can improve commercialization expectations for AstraZeneca’s oncology franchise.
What to watch
No details are provided on pricing, reimbursement status, or expected launch timeline in India, which can dominate real-world uptake.
Background
The approval targets adults with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.
Ticker impact
AstraZeneca said CDSCO approved an additional indication for trastuzumab deruxtecan in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Moderate positive bias for AZN, mainly via sentiment and incremental commercial upside rather than a step-change.
The article is a first report of a new CDSCO indication, but it provides no commercial sizing, uptake assumptions, or financial guidance, limiting magnitude.
Market effects
Adds to the competitive evidence base for HER2-targeted antibody-drug conjugates in early-stage settings, potentially intensifying payer and guideline discussions.
Improves AstraZeneca’s addressable market in India for HER2-positive early breast cancer patients with residual disease after neoadjuvant therapy.
May reinforce global confidence in the DESTINY-Breast05 read-through, though the approval is India-specific in this report.
Counterpoint
India-only label expansion may not translate into material revenue upside without data on prescribing behavior, reimbursement, and patient volumes.
Key entities
- companyAstraZeneca
Sponsor of trastuzumab deruxtecan; received CDSCO approval for an additional early breast cancer indication in India.
- regulatorCDSCO
India’s Central Drugs Standard Control Organisation that approved the additional indication.
- drugtrastuzumab deruxtecan
HER2-targeted antibody-drug conjugate; approved for adjuvant treatment in a defined residual disease population.
- clinical_trialDESTINY-Breast05
Trial whose results support the new indication approval.
